To determine whether miR‐206 is involved in IL‐6/STAT3 signalling to regulate gefitinib sensitivity in lung cancer, we evaluated the expression of miR‐206 and IL‐6 in 37 NSCLC patients harbouring EGFR mutations and 14 healthy participants as IL‐6 secreted by tumour cells was postulated as a potential mechanism for the primary resistance or low sensitivity to EGFR‐TKIs.37 The patients' backgrounds and clinical characteristics are listed in Table S1. The gene discussed is IL6; the disease is neoplasm.